Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHQ880 in high-risk smoldering multiple myeloma
NCT01302886Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2011
- Primary completion
- Nov 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of BHQ880 in smoldering multiple myeloma (SMM), sponsored by Novartis. Started May 2011; status: completed.
02
Drugs
BHQ880
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT01302886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302886.